Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
HAJBI, Farid EL
ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over	Recruiting	3	774	Europe	LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine	Federation Francophone de Cancerologie Digestive	Colonic Adenocarcinoma	12/24	08/25
ImadGist, NCT02260505: Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)	Completed	3	136	Europe	Imatinib maintenance, Glivec, Imatinib mésilate	Centre Leon Berard	Gastrointestinal Stromal Tumors, Resected Gastrointestinal Stromal Tumors, Non-metastatic, High Risk of Recurrence, KIT Gene Mutation	12/23	12/23
SCARCE, NCT03519295 / 2017-003185-27: A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma	Active, not recruiting	2	99	Europe	MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil	GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG	Anal Cancer	02/23	12/24
ARION, NCT03777813 / 2018-000708-40: Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer	Active, not recruiting	2	112	Europe	Durvalumab, IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)	UNICANCER	Esophagus Cancer, Unresectable Malignant Neoplasm	09/25	09/25